Xilio Therapeutics Inc. logo

Xilio Therapeutics Inc.

XLO | NASDAQ
Chart Builder DCF Calculator
$9.04
+$0.02 (+0.22%)
At close: Sep 22, 2026, 4:00 PM ET
$9.04
$0 (0.00%)
After-hours: Sep 22, 2026, 4:10 PM ET

Market Data

Market Cap
$59.31M
Enterprise Value
$-70.43M
Beta
-0.12
Average Volume
38.52K
Shares Outstanding (Diluted)
19.4M
Shares Change YoY
424.17%
Institutional Ownership
13.50%
Exchange
NASDAQ
ISIN
US98422T2096

Price Performance

Price Change 1M
-3.2%
Price Change 3M
1.4%
Price Change 6M
5.7%
Price Change YTD
-4.0%
Price Change 1Y
-15.8%
Price Change 3Y
-71.0%
Price Change 5Y
-96.0%
1M CAGR (ann.)
-1.6%
1Y CAGR (ann.)
-15.6%
5Y CAGR (ann.)
N/A
All-Time CAGR
-48.0%

Valuation

PE Ratio
-5.50
Forward PE
1.54
PEG Ratio
-0.03
Forward PEG
0.44
PS Ratio
0.93
Forward PS
2.20
PB Ratio
0.82
P/FCF Ratio
-0.97
P/Adj. FCF Ratio
-0.86
P/OCF Ratio
-2.89
EV/Sales
-1.10
EV/EBIT
3.23
EV/EBITDA
3.44
EV/FCF
1.15
Earnings Yield
-18.2%
FCF Yield
-103.3%
Adj. FCF Yield
-116.6%

Financial Health

Net Cash
$136.04M
Total Debt
$6.3M
Cash & Short-Term Investments
$136.04M
Total Assets
$154.25M
Current Ratio
4.25
Quick Ratio
4.25
Debt / Equity Ratio
0.09
Debt / EBITDA
-0.31
Debt / FCF
-0.10
OCF / Debt
-9.61
Interest Coverage
0.00
Altman Z-Score
-2.70
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
99.5%
Operating Profit Margin
-48.9%
EBITDA Margin
-32.0%
Net Profit Margin
-34.1%
FCF Margin
-95.6%
Adj. FCF Margin
-107.9%
SBC / Revenue
12.3%
SBC Impact (per share)
-12.8%

Returns

Return on Assets
-14.2%
Return on Equity
-50.8%
Return on Invested Capital
-25.8%
Return on Capital Employed
-26.1%
Return on Tangible Assets
-14.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
113.7%
Revenue CAGR 5Y
87.9%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
96.7%
EPS CAGR 5Y
82.4%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-71.3%
FCF CAGR 5Y
19.7%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
3
EPS Growth Next 3Y
-29.5%
Revenue Growth Next 3Y
-61.7%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.82
EPS Growth Est (next Q)
-46.8%
Revenue Est (next Q)
$4.84M
Revenue Growth Est (next Q)
-74.6%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$98
Price Target Upside
986.5%

Cash Flow

Operating Cash Flow
$-60.6M
Free Cash Flow
$-61.27M
Adj. Free Cash Flow
$-69.13M
FCF Per Share
-$3.16
OCF Per Share
-$3.12
OCF/S Ratio
-94.5%

Income Statement

Revenue
$64.09M
Gross Profit
$63.75M
Operating Income
$-31.37M
EBITDA
$-20.49M
Net Income
$-21.83M
EPS (Diluted)
-$1.64
Revenue / Employee
$843.32K
Profit / Employee
$-287.22K
Employees
76

© 2026 bestshares.com. All rights reserved.